A Strategic Leap for Bristol Myers’ Cell Therapy Empire
“This acquisition enhances our robust cell therapy research platform and provides an opportunity to advance a potential best-in-class therapy designed to deplete autoreactive B cells and reset the immune system,” said Robert Plenge, Bristol Myers’ chief research officer.
The deal gives Bristol Myers a powerful new weapon in its growing immunology and RNA arsenal, complementing its existing CAR T-cell therapies and pipeline in autoimmune and inflammatory diseases.
Orbital’s work, meanwhile, represents a critical link in bridging cell therapy and RNA engineering, creating what both companies see as the next frontier in precision medicine.
A “Transformational Moment” for Orbital Therapeutics
For Orbital, the acquisition marks a milestone in its evolution from a promising biotech startup to a major player in the next wave of therapeutic innovation.
“Since inception, Orbital has made significant strides developing a differentiated RNA platform designed to enable a new generation of RNA medicines that reach more tissues, address more diseases, and benefit more patients,” said Ron Philip, Orbital’s CEO. “The promising early data from our lead program, OTX-201, underscore the strength of this approach and the potential of our integrated RNA technologies.”
Orbital’s leadership will reportedly continue to collaborate with Bristol Myers’ cell therapy division as the integration moves forward.
